The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

News and Analysis Published: June 2009 Tapping into combination pills for HIV Bethan Hughes Nature Reviews Drug Discovery 8, 439–440 (2009) Cite this article ...